3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hematologic Neoplasms
4
Thrombocytopenia
2
Hemorrhage
2
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
85
fludarabine phosphate
84
Peripheral Blood Stem Cell Transplantation
70
Mycophenolic Acid
58
Tacrolimus
57
Whole-Body Irradiation
55
Busulfan
54
Antilymphocyte Serum
47
Cyclosporine
45
Methotrexate
38
fludarabine
37
Filgrastim
37
Melphalan
32
Radiotherapy
27
Cytarabine
27
Etoposide
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Azacitidine
18
Sirolimus
15
Granulocyte Colony-Stimulating Factor
15
Flow Cytometry
14
Cyclosporins
14
thymoglobulin
13
Specimen Handling
13
Alemtuzumab
13
Biopsy
12
venetoclax
10
Thiotepa
10
Decitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tranexamic Acid
×
Other hematologic neoplasm
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled